Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Operating Expenses (2021 - 2023)

Historic Operating Expenses for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to $45.5 million.

  • Cullinan Therapeutics' Operating Expenses rose 3949.03% to $45.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $190.6 million, marking a year-over-year increase of 4428.13%. This contributed to the annual value of $196.9 million for FY2024, which is 328.88% up from last year.
  • Per Cullinan Therapeutics' latest filing, its Operating Expenses stood at $45.5 million for Q4 2023, which was up 3949.03% from $44.8 million recorded in Q3 2023.
  • In the past 5 years, Cullinan Therapeutics' Operating Expenses ranged from a high of $62.8 million in Q1 2023 and a low of $16.6 million during Q2 2021
  • For the 3-year period, Cullinan Therapeutics' Operating Expenses averaged around $34.1 million, with its median value being $33.5 million (2021).
  • Over the last 5 years, Cullinan Therapeutics' Operating Expenses had its largest YoY gain of 12347.63% in 2022, and its largest YoY loss of 506.3% in 2022.
  • Over the past 3 years, Cullinan Therapeutics' Operating Expenses (Quarter) stood at $34.3 million in 2021, then fell by 5.06% to $32.6 million in 2022, then surged by 39.49% to $45.5 million in 2023.
  • Its Operating Expenses was $45.5 million in Q4 2023, compared to $44.8 million in Q3 2023 and $37.6 million in Q2 2023.